ATE175446T1 - Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung - Google Patents
Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindungInfo
- Publication number
- ATE175446T1 ATE175446T1 AT91911895T AT91911895T ATE175446T1 AT E175446 T1 ATE175446 T1 AT E175446T1 AT 91911895 T AT91911895 T AT 91911895T AT 91911895 T AT91911895 T AT 91911895T AT E175446 T1 ATE175446 T1 AT E175446T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- connection
- immunogenic peptides
- receptor binding
- disclosed
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010041397 CD4 Antigens Proteins 0.000 abstract 1
- 102100034353 Integrase Human genes 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 108010078428 env Gene Products Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52463290A | 1990-05-16 | 1990-05-16 | |
US66907291A | 1991-03-14 | 1991-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE175446T1 true ATE175446T1 (de) | 1999-01-15 |
Family
ID=27061560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91911895T ATE175446T1 (de) | 1990-05-16 | 1991-05-16 | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung |
Country Status (7)
Country | Link |
---|---|
US (2) | US5817316A (de) |
EP (1) | EP0651818B1 (de) |
JP (1) | JPH05507491A (de) |
AT (1) | ATE175446T1 (de) |
CA (1) | CA2082948C (de) |
DE (1) | DE69130741T2 (de) |
WO (1) | WO1991017764A1 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0554401A4 (en) * | 1990-10-26 | 1996-10-30 | New York Health Res Inst | Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 |
JPH05262662A (ja) * | 1991-07-15 | 1993-10-12 | Calpis Food Ind Co Ltd:The | Hiv重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法 |
US5558865A (en) * | 1991-08-22 | 1996-09-24 | Nissin Shokuhin Kabushiki Kaisha | HIV immunotherapeutics |
EP0581353A1 (de) * | 1992-07-03 | 1994-02-02 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Monoklonale Antikörper gegen HIV-1 gp120, Zellinien die sie herstellen und entsprechende Epitope-Strukturen |
US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
WO1999024464A1 (en) | 1997-11-10 | 1999-05-20 | Dana-Farber Cancer Institute, Inc | Glycosylated modified primate lentivirus envelope polypeptides |
US6908617B1 (en) | 1997-11-10 | 2005-06-21 | Dana-Farber Cancer Institute, Inc. | Glycosylated modified primate lentivirus envelope polypeptides |
US6679851B2 (en) * | 1998-09-01 | 2004-01-20 | Senorx, Inc. | Tissue accessing and anchoring device and method |
US7585839B2 (en) * | 2000-02-23 | 2009-09-08 | Zealand Pharma A/S | Medical uses of intercellular communication facilitating compounds |
US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
WO2001083535A2 (en) * | 2000-05-02 | 2001-11-08 | Simon Fraser University | Polypeptides for use as a vaccine and/or treatment for hiv infection |
CA2431212A1 (en) * | 2000-12-27 | 2002-07-25 | Richard T. Wyatt | Immunogenic proteoliposomes, and uses thereof |
JP4307841B2 (ja) | 2001-03-22 | 2009-08-05 | アメリカ合衆国 | グリコシル化抵抗性シアノビリン及び関連コンジュゲート、組成物、核酸、ベクター、宿主細胞、非グリコシル化シアノビリンの製造方法及び使用方法 |
AU2003299489B2 (en) * | 2002-05-10 | 2009-01-15 | The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc | Interacting site for gp41 on gp120 of HIV-1 |
JP3849584B2 (ja) * | 2002-06-07 | 2006-11-22 | トヨタ自動車株式会社 | 蒸発燃料処理装置 |
WO2004110384A2 (en) * | 2003-06-12 | 2004-12-23 | Vaxgen, Inc. | Hiv-1 envelope glycoproteins having unusual disulfide structure |
EP1664784A1 (de) * | 2003-09-17 | 2006-06-07 | Guava Technologies, Inc. | Zusammensetzungen und verfahren zur analyse von zielsubstanzen |
CA2637600A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
WO2009010733A2 (en) * | 2007-07-15 | 2009-01-22 | Zealand Pharma A/S | Peptide gap junction modulators |
CN102639149A (zh) | 2009-03-05 | 2012-08-15 | 哈佛学院董事会 | 分泌的aP2及其抑制方法 |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
EP2492279A1 (de) * | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
CA2850745C (en) | 2011-10-03 | 2022-12-13 | Duke University | Vaccine |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3288584A2 (de) | 2015-04-30 | 2018-03-07 | President and Fellows of Harvard College | Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen |
AU2018279950A1 (en) | 2017-06-09 | 2020-01-30 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
WO2020159941A1 (en) * | 2019-01-28 | 2020-08-06 | Xyphos Biosciences Inc. | Modified non-natural nkg2d ligands that selectively deliver attached heterologous molecules to non-natural nkg2d receptors on car-cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE151638T1 (de) * | 1987-02-20 | 1997-05-15 | Genentech Inc | Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern |
US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
-
1991
- 1991-05-16 JP JP91511185A patent/JPH05507491A/ja active Pending
- 1991-05-16 DE DE69130741T patent/DE69130741T2/de not_active Expired - Fee Related
- 1991-05-16 AT AT91911895T patent/ATE175446T1/de not_active IP Right Cessation
- 1991-05-16 WO PCT/US1991/003472 patent/WO1991017764A1/en active IP Right Grant
- 1991-05-16 CA CA002082948A patent/CA2082948C/en not_active Expired - Fee Related
- 1991-05-16 EP EP91911895A patent/EP0651818B1/de not_active Expired - Lifetime
-
1992
- 1992-03-26 US US07/858,165 patent/US5817316A/en not_active Expired - Fee Related
-
1993
- 1993-10-12 US US08/135,312 patent/US5858366A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1991017764A1 (en) | 1991-11-28 |
EP0651818B1 (de) | 1999-01-07 |
DE69130741T2 (de) | 1999-07-29 |
JPH05507491A (ja) | 1993-10-28 |
DE69130741D1 (de) | 1999-02-18 |
CA2082948A1 (en) | 1991-11-17 |
EP0651818A1 (de) | 1995-05-10 |
CA2082948C (en) | 2000-07-11 |
US5858366A (en) | 1999-01-12 |
EP0651818A4 (de) | 1993-08-09 |
US5817316A (en) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE175446T1 (de) | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung | |
EP0679093A1 (de) | Methode zum überbringen von agenzien an zielzellen. | |
ATE404583T1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
HK1012841A1 (en) | Pharmaceutical composition for the treatment or prevention of amalignant tumor | |
NO891711L (no) | Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr. | |
EP0434713A4 (en) | Hiv-1 envelope muteins lacking hypervariable domains | |
CZ105795A3 (en) | Pharmaceutical preparation containing antagonists of vascular endothelial cell growth factor | |
CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
DE3588254D1 (de) | Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen | |
PL336295A1 (en) | Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna | |
AU7565991A (en) | Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy | |
ES2013328A6 (es) | Un metodo para detectar anticuerpos contra antigenos hiv-1. | |
ES2010727A6 (es) | Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv. | |
ATE238065T1 (de) | Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus | |
IL127595A0 (en) | Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens the DNA encoding them and the process for their preparation and use | |
TR199800912T2 (xx) | T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul. | |
EP0344006A3 (de) | Peptide, welche die Bindung von HIV-1 zum CD4-Rezeptor-Protein blockieren | |
NZ333203A (en) | Tumour antigen proteins, genes thereof, and tumour antigen peptides | |
EP0369816A3 (de) | Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper | |
AU4712993A (en) | New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods | |
ATE317851T1 (de) | Polypeptide mit aminosäuresequenzen aus dem n- terminalen bereich von gp116 von cytomegalovirus und deren verwendung bei der diagnostik, prophylaxe und therapie | |
NO923415L (no) | Forbedrede chimere toksiner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |